UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported) December 17, 2001
Commission File Number 001-10304
AMEXDRUG CORPORATION
--------------------
(Exact Name of Registrant as Specified in its Charter)
Nevada 95-2251025
------ ----------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)
396 South Doheny Drive, Suite 326
---------------------------------
Beverly Hills, California 90211
-------------------------------
(Address of principal executive offices)
(Zip Code)
(310) 855-0475
--------------
(Registrant's Executive Office Telephone Number)
1
Item 8. Change in Fiscal Year
On December 21, 2001, Amexdrug Corporation, a California corporation
("Amex CA") filed a Current Report on Form 8-K disclosing that for purposes of
redomiciling the Company from California to Nevada, Amex CA entered into a
Merger Agreement with Amexdrug Corporation, a Nevada corporation, ("Amex NV"),
with Amex NV being the surviving corporation.
The Company inadvertently failed to disclose that the fiscal year end
of the surviving entity is December 31. Accordingly, at the time of the merger,
the Company changed its fiscal year end from June 30 to December 31. The first
report affected by this change will be the 10- KSB report for the year ended
December 31, 2001, which the Company will file within 90 days of December 31,
2001.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Current Report on Form 8-K to be signed on
its behalf by the undersigned hereunto duly authorized.
AMEXDRUG CORPORATION
Date: February 21, 2001 By /s/ Jack Amin
---------------------------------------------
Jack Amin, President, Chief Financial Officer
2